Humoral Responses in the Omicron Era following Three-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients

Caitríona M. McEvoy,^{1,2,3}* Queenie Hu,^{4§} Kento T. Abe,^{4,5§} Kevin Yau,^{3,6} Matthew J. Oliver,^{3,6,7} Adeera Levin⁸, Anne-Claude Gingras,^{4,5} Michelle A. Hladunewich,^{3,6,7} Darren A. Yuen.^{1,2,3}

¹ St. Michael's Hospital Keenan Research Centre for Biomedical Science, Unity Health Toronto, Toronto, ON, Canada

² Division of Nephrology, Department of Medicine, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada

³ University of Toronto Temerty Faculty of Medicine, Toronto, ON, Canada

⁴ Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Toronto, ON, Canada

⁵ Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

⁶ Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

⁷ Ontario Renal Network, Ontario Health, Toronto, ON, Canada

⁸ UBC Division of Nephrology, St Paul's Hospital, Vancouver, BC, Canada

§ These authors contributed equally

*corresponding author:

Caitríona McEvoy, Rm 509, 5th Floor, Li Ka Shing Knowledge Institute, St. Michael's Hospital, 209 Victoria Street, Toronto, Ontario, Canada M5B 1T8. Phone: 416.864.6060 ext. 77366; Email: mcevoyc@gmail.com.

Word count: 9,181

Keywords: COVID-19, Humoral response, Vaccines, Kidney Transplant, Omicron

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background:

Kidney transplant recipients (KTR) have a diminished response to SARS-CoV-2 vaccination in comparison to immunocompetent individuals. Deeper understanding of the antibody response in KTRs following third-dose vaccination would enable identification of those who remain unprotected against Omicron and require additional treatment strategies.

Methods:

We profiled antibody responses in KTRs pre- and at one and three months post-third-dose SARS-CoV2 mRNA-based vaccine. Anti-spike and anti-RBD IgG levels were determined by ELISA. Neutralization against wild-type, Beta, Delta and Omicron (BA.1) variants was determined using a SARS-CoV-2 spike pseudotyped lentivirus assay.

Results:

44 KTRs were analysed at 1 and 3 months (n=26) post-third-dose. At one month, the proportion of participants with a robust antibody response had increased significantly from baseline, but Omicron-specific neutralizing antibodies were detected in just 45% of KTRs. Median binding antibody levels declined at 3 months, but the proportion of KTRs with a robust antibody response was unchanged. 38.5% KTRs maintained Omicron-specific neutralization at 3 months. No clinical variables were significantly associated with detectable Omicron neutralizing antibodies, but anti-RBD titres appeared to identify those with Omicron-specific neutralizing capacity.

Conclusion:

Over 50% of KTRs lack an Omicron-specific neutralization response 1 month following a third mRNA-vaccine dose. Among responders, binding and neutralizing antibody responses

were well preserved at 3 months. Anti-RBD antibody titres may be a useful identifier of

patients with detectable Omicron neutralizing antibody response.

Trial registration: Clinical Trials Ontario: ID 3604

Funding: Funded by the St. Michael's Hospital Foundation (CMM, DAY) and the Public

Health Agency of Canada, through the COVID-19 Immunity Task Force (MAH, MJO, AL).

Introduction

Solid organ transplant recipients (SOTRs) and patients with chronic kidney disease are at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and adverse outcomes (1-4). Consequently, kidney transplant recipients (KTRs) represent an especially vulnerable population and a priority group for vaccination. While offering some degree of protection, the humoral response observed following two doses of SARS-CoV-2 vaccine among transplant recipients in general, and KTRs in particular, is inferior to immunocompetent individuals, as is the real world effectiveness of two dose vaccination in this population (5-11).

The improved immunogenicity observed in transplant recipients following a third dose of mRNA vaccine (12-15) led to the recommendation for a primary vaccine series of three doses in this population (16). Subsequent studies have shown augmented binding antibody levels and enhanced neutralizing capabilities following the third vaccine dose in SOTR cohorts, at one and three month timepoints (17, 18). However, diminished responses in KTRs relative to other organ groups have been reported (5, 19), and data on the durability of the antibody response beyond one month in KTR cohorts are lacking.

In late 2021, the Omicron SARS-CoV-2 variant emerged and rapidly gained dominance worldwide. The first Omicron wave related to the BA.1 (B.1.1.159.1) subvariant; however, in recent months another Omicron subvariant, BA.2, has predominated (20, 21). Due to a large number of mutations in the receptor binding domain (RBD) – the main target of neutralizing antibodies – Omicron subvariants can substantially evade the pre-existing

humoral neutralization response induced by vaccines or infection (22-26). Importantly, in comparison to a two-dose strategy, a third dose of an mRNA SARS-CoV-2 vaccine has been shown to substantially boost neutralizing antibody titres against Omicron in the general population (25, 27), and to reduce overall infection rates and mortality (28, 29). However, data on neutralizing capacity of KTR plasma to Omicron after additional vaccine doses remain limited. Published studies to-date have focused only on SOTRs (30) or have short (1 month) follow up (31, 32). Moreover, it remains unknown if the correlations previously identified between binding and neutralizing antibodies and protection from infection (33, 34) translate directly to an era in which the highly mutated Omicron subvariants predominate worldwide.

A deeper understanding of the immune response that is predictive of protection from Omicron subvariants would direct future vaccine and pre-exposure prophylaxis strategies in this vulnerable population. Therefore, we conducted a prospective observational study in a cohort of KTRs to comprehensively profile the binding and neutralizing antibody responses at one and three months following the third vaccine dose, and to compare the induced neutralization response with a cohort of healthy controls.

Results

Patient characteristics and baseline humoral response

Pre- and post-third dose blood samples were available for 44 KTRs. Baseline demographic and clinical characteristics are shown in **Table 1**. Median age was 55.5 years (interquartile range (IQR), 45.8 to 63 years), and 79.5% of the population was male. The median time from transplant was 43.1 months (IQR, 7 to 142 months). All patients were on a calcineurin

inhibitor (CNI), with the majority (91%) taking tacrolimus. 70% were taking an antimetabolite (mycophenolic acid-based in all cases), 93% of patients were taking prednisone, and in total, 31/44 (70.5%) were on a standard triple-agent immunosuppressive regimen at the time of the third vaccine dose. All participants had previously received two doses of an mRNA-based vaccine, with 35 (79.5%) having received Pfizer-BioNTech BNT162b2, and 8 (18.1%) having been given Moderna mRNA-1273. 26 of the 44 patients (59%) were also tested at 3 months post-third dose. This group had similar clinical and demographic characteristics to the larger parent cohort (**Table 1**).

The baseline demographics of the healthy controls (n= 13) are shown in **Supplemental Table 1**. Their median age was 46 years (interquartile range (IQR), 31 to 55 years), and 30.7% of the population was male. All healthy controls had received the Pfizer-BioNTech BNT162b2 vaccine for their initial two doses.

Anti-RBD, anti-spike and anti-nucleocapsid IgG were measured in plasma before and after a third dose of an mRNA-based SARS-CoV-2 vaccine in KTRs. As described previously (35), the threshold for seropositivity (seroconversion) was determined as \geq 3 standard deviations from the log means of aggregated data from archived (pre-SARS-CoV-2 era) negative sera. We considered the median levels of convalescent serum (taken 21–115 days after symptom onset in a cohort of 211 patients in the general population who had mild to severe SARS-CoV-2), as reflective of a robust antibody response (35, 36).

At a median time of 149.5 days (IQR 124-174) post-second vaccine dose, 24/44 (54.5%) and 33/44 (75%) KTRs were seropositive for anti-RBD and anti-spike antibodies, respectively

(**Table 2**). However, just 6.8% (3/44) and 18.2% (8/44) of patients had anti-RBD and antispike antibody levels consistent with a robust antibody response i.e. exceeding the median convalescent serum levels seen in healthy controls (35) (**Figure 1A-B**). Prior to the third dose, previous SARS-CoV-2 infection had been confirmed by PCR- or rapid antigen-testing in 2/44 patients. However, only 1 of the cases with prior SARS-CoV-2 infection was seropositive for anti-nucleocapsid antibody (**Supplemental Figure 1A**). An additional patient with no known history of SARS-CoV-2 infection was also seropositive for anti-nucleocapsid antibody. In both cases, the titres remained below the median convalescent response observed in healthy controls (35).

Humoral response at 1 and 3 months post-third mRNA vaccine dose

At a median of 26.5 days post-third vaccine dose, 33 (75%) and 39 (88.6%) KTRs were seropositive for anti-RBD and anti-spike antibodies, respectively. In comparison to pre-third dose serology, anti-spike and anti-RBD antibody levels had significantly increased in our KTR cohort (anti-spike fold increase 1.66, anti-RBD fold increase 5.65; p= 3.65×10^{-10} and 7.51×10^{-10} , respectively) (**Figure 1A-B**).

A greater proportion of KTRs now exhibited a robust response, as defined by anti-spike antibody (28/44 (63.6%) participants, $p=5.1 \times 10^{-5}$) and anti-RBD antibody (20/44 (45.5%), p=0.001) values above the median levels measured in convalescent healthy controls (**Figure 1A-B**). Although a substantial number of participants remained seronegative at all timepoints tested, 6/11 (54%) and 9/20 (45%) of patients who were seronegative at baseline had seroconverted with respect to anti-spike and anti-RBD antibodies when assessed one month following the third vaccine dose. Anti-spike and anti-RBD antibody

levels were highly correlated among individuals (Spearman's rho 0.82, p < 2.2×10^{-16} , Supplemental Figure 1B).

In total, 35/44 (79.6%) and 7/44 (15.9%) of KTRs received three doses of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), respectively, with 2 KTRs (4.5%) receiving a mixed vaccine series. The majority of those who received mixed vaccine, or Moderna-only regimens had binding antibody titres consistent with a robust response at Month 1; however, differences in proportions were not statistically significant (anti-RBD adjusted p values 0.09 (Pfizer-BioNTech vs. Moderna); 0.14 (Pfizer-BioNTech vs. Mixed); and 1 (Moderna vs. Mixed)), anti-Spike p= 0.59 (**Supplemental Figure 2A-B**). Likewise, anti-RBD and anti-spike antibody levels were not significantly different between Pfizer-BioNTech-only, Moderna-only and mixed vaccination groups (anti-RBD p = 0.1, anti-spike p = 0.22, **Supplemental Figure 2C-D**).

In 26/44 patients, antibodies were further assessed at 3 months. At a median time of 84.5 days post-third vaccine dose, 15 (57.7%) and 23 (88.5%) of patients were seropositive for anti-RBD and anti-spike antibodies, respectively. There was a significant decrease in the anti-RBD antibody levels of the overall group ($p = 8.2 \times 10^{-5}$), while the decline in anti-spike antibody levels was not significant (p = 0.87) (**Figure 1C-D**). Despite the decline in antibody levels, the proportion of the patients in this group exhibiting a robust antibody response with either anti-spike or anti-RBD was not significantly altered (anti-spike: p = 1, anti-RBD: p = 0.48). Exploring this further, we confirmed that participants who mounted a robust antibody response with either anti-spike or anti-spike or anti-RBD antibodies when tested one month post-third dose, experienced a more modest attrition of antibody levels by Month 3 when

compared to patients who exhibited a partial response at Month 1, as defined by seropositivity not reaching median convalescent levels in healthy controls (anti-RBD: p =0.012, anti-spike: p = 0.57) (**Supplemental Figure 3A-C**). Similar to the Month 1 response, anti-spike and anti-RBD antibody levels remained highly correlated (Spearman's rho 0.89, p = 1.6×10^{-6} , **Supplemental Figure 4A**). Finally, although 1 patient in this group had a prior history of SARS-CoV-2 infection, all patients were seronegative for anti-nucleocapsid antibody at this timepoint (**Supplemental Figure 4B**).

SARS-CoV-2 Neutralization at 1 and 3 months following third dose

Neutralization capacity at baseline, and at one and three months post-third vaccine dose was assessed for wild-type (WT), B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron BA.1) SARS-CoV-2 variants (Table 2). Prior to receiving their third dose, 21/44 (47.7%), 11/44 (25%), and 14/44 (31.8%) participants had detectable neutralizing antibodies to WT, Beta, and Delta, respectively (Figure 2A). One month post-third dose, the majority of the cohort had detectable neutralizing antibody responses against WT (32/44 (72.7%)), Beta (25/44 (56.8%)) and Delta (28/44 (63.6%)) with median log₁₀ID₅₀ against WT: 3.28 (IQR 2.62– 3.55); Beta 2.76 (IQR 2.26 - 3.15); Delta (3.01 (IQR 2.52 - 3.37)) in the subgroup of positive patients. The proportion of participants with neutralizing antibodies against the WT, Beta and Delta variants had significantly increased compared to baseline (WT: p = 0.026; Beta: p = 0.005; Delta p = 0.005) (Figure 2A). No participants had detectable neutralizing antibodies to Omicron prior to third-dose vaccination; however, this was detected in 20/44 (45.5%) of participants after one month (p = 0.0037), with a median log₁₀ID₅₀ of 2.49 (IQR 1.93–2.86) in the subgroup of positive patients. The proportion of participants with neutralizing antibody against Omicron was significantly lower than those with detectable neutralizing antibody

against WT and Delta variants, but not against Beta (p = 0.002 WT versus Omicron, p = 0.074Beta versus Omicron, p = 0.013 Delta versus Omicron). We assessed the impact of vaccine type on the presence or absence of neutralizing antibodies against each variant; however, no significant associations were identified (WT: p = 0.81, Beta: p = 0.15, Delta p = 0.25, Omicron p = 0.21, **Supplemental Figure 5**).

In the sub-group of patients with blood samples at three months post-third dose, levels of neutralizing antibodies were reduced in comparison to the month 1 timepoint with median $log_{10}lD_{50}$ against WT: 2.84 (IQR 2.18– 3.40), Beta 2.51 (IQR 2.19 - 3.08), Delta (2.66 (IQR 2.09 – 3.21), and Omicron (2.16 (IQR 1.87-2.66)) in the subgroup of positive patients. Despite this decline, the proportion of patients with detectable neutralization response to individual variants had not significantly altered compared to the month 1 timepoint (p = 1 for all comparisons) (**Figure 2B**). At this time point, a smaller proportion of patients had detectable neutralizing antibodies against Omicron (10/26) as compared to WT (16/26, p = 0.041), Beta (12/26, p = 0.48) and Delta (14/26, p = 0.11).

As compared to WT, neutralizing antibody responses ($log_{10}ID_{50}$) were several fold-lower for Beta (median fold reduction 3.4 (IQR 1-7.34), Delta (median fold reduction 1.82 (IQR 1 – 3.50), and most strikingly, Omicron (median fold reduction 11.51 (IQR 1- 33.97) in patients with detectable neutralizing antibodies at 1 month and to a lesser extent at 3 months (median fold reductions Beta (2.52 (IQR 1-4.36)), Delta (1.55 (IQR 1-2.62)) and Omicron (6.77 (IQR 1-14.22), **Supplemental Figure 6**).

Comparison of SARS-CoV-2 antibody responses with healthy controls

The presence and magnitude of binding and neutralizing antibody responses at one month following the third vaccine dose in KTRs was next compared to a cohort of 13 healthy controls. The baseline demographics and vaccination details of this cohort are presented in **Supplemental Table 1**. The magnitude of binding antibody response among healthy controls was increased in comparison to KTRs (anti-spike 1.28 fold increase, anti-RBD 1.58 fold increase). In notable contrast to the KTRs, all healthy controls were categorized as exhibiting a robust response one month after the third vaccine dose (**Supplemental Figure 7 and Supplemental Table 2**).

In contrast to KTRs, neutralizing antibodies against Omicron were detected in 5/13 (38.5%) healthy controls prior to receipt of the third vaccine dose. Additionally, 100% of healthy controls had detectable neutralizing antibodies against all variants, including Omicron, when tested at the 1 month timepoint (**Figure 3 and Supplemental Table 2**). As observed in the transplant population, neutralization antibody responses were several fold-lower for Beta (median fold reduction 2.26 (IQR 1.62-2.74), Delta (median fold reduction 1.83 (IQR 1.45-2.27), and Omicron (median fold reduction 15.18 (IQR 9.29-18.68), vs. WT at 1 month in healthy controls (**Supplemental Figure 8**).

We next focused on the subgroup of 'responding KTRs' i.e. those who had detectable neutralizing antibody to an individual variant at 1 month following the third vaccine dose. We compared the median $log_{10}ID_{50}$ of healthy controls with that of the responding KTRs, and found that while the magnitude of response in relation to WT, Beta and Delta variants was significantly lower in KTRs (median $log_{10}ID_{50}$ fold reduction in KTRs: WT (0.494, p = 0.003), Beta (0.641, p = 0.003), Delta (0.595, p = 0.002)), there was no significant difference in the median $log_{10} ID_{50}$ of responding KTRs and our population of healthy controls against the Omicron variant ($log_{10}ID_{50}$ fold reduction in KTRs: Omicron (0.1, p=0.27)) (Figure 4).

Assessment of responders and non-responders

A number of individuals remained below the threshold of seropositivity for anti-spike and/or anti-RBD antibodies, or had no detectable SARS-CoV-2 neutralization capabilities. As Omicron subvariants are currently dominant worldwide, we reasoned that one of the most important measurable humoral responses would be the presence of Omicron-specific neutralization antibodies. Therefore, we next explored if any demographic and transplantrelated clinical factors of our study population associated with the development of Omicron-specific neutralizing antibodies. Individuals lacking a detectable Omicron neutralizing response tended to be older, have a longer transplant vintage, a lower estimated glomerular filtration rate (eGFR), and to have received mainly deceased donor organs; however, no significant associations were identified (Table 3). Likewise, no baseline demographic or clinical/transplant characteristics identified people who were nonresponders against all variants (n=12), as compared to people with detectable neutralizing antibody against at least one variant (n=32), though responders tended to have a longer interval time between receipt of vaccine doses 2 and 3 (Table 4). Serum levels of anti-spike and anti-RBD antibodies were significantly higher in Omicron-specific responders (compared to Omicron non-responders) (anti-spike $p = 1.1 \times 10^{-7}$, anti-RBD $p = 4 \times 10^{-7}$) and in individuals who had detectable neutralizing antibody against one variant (compared to nonresponders for all variants) (anti-spike $p = 1.1 \times 10^{-7}$, anti-RBD $p = 1.1 \times 10^{-9}$) (Supplemental Figure 9).

As anti-RBD and anti-spike IgG antibody levels at Month 1 strongly correlated with neutralizing antibody levels (Log₁₀ID₅₀) at both Month 1 and Month 3 (**Supplemental Figure 10**), we next performed receiver operating curve (ROC) analysis to identify the threshold values of anti-RBD and anti-spike antibodies at one month following the third vaccine dose that were associated with the presence of neutralizing antibody against individual variants (**Figure 5**). To maximise specificity, the optimal cut-off was determined by calculating the top-left most point of each curve. For the WT, Beta, and Delta strains, the anti-RBD and antispike antibodies had comparable areas under the curve (AUCs), though the thresholds identified for anti-RBD were associated with zero false positives, in contrast to a minimal rate of false positives using the anti-spike threshold (**Supplemental Table 3**). The AUCs were reduced in the case of Omicron (anti-RBD 0.91, anti-spike 0.925), with 3 false positives using the anti-RBD antibody threshold identified, and 4 false positives using the anti-spike antibody threshold identified.

The optimal thresholds for anti-spike antibody levels that best identified neutralization capacities against all variants tested (WT: 1.319, Beta: 1.481, Delta: 1.391, and Omicron: 1.475) approximated the median convalescent antibody level seen in recovered healthy controls (1.38). In contrast, the anti-RBD antibody thresholds that best identified neutralization capacity against each variant (WT: 0.317, Delta: 0.627, and Beta: 0.932) were above the seropositivity threshold (0.186), but below the median convalescent response value of 1.25. Notably, in the case of Omicron, the optimal thresholds identified for both anti-spike (1.475) and anti-RBD (1.198) antibodies approximated or exceeded the median convalescent response, suggesting the requirement for a robust level of these antibodies as an identifier of Omicron neutralization capacity.

Discussion

In this study, we comprehensively profiled the binding and neutralizing antibody responses up to three months following a third dose of mRNA SARS-CoV-2 vaccine in a KTR cohort. The majority of participants had detectable anti-spike and anti-RBD antibodies at one and three months following the third vaccine dose. Our principal findings are: 1) the proportion of patients whose antibody titres were consistent with a robust immune response rose significantly following a booster dose; 2) those who responded robustly at Month 1 had a preserved humoral response at Month 3; and 3) we define anti-RBD and anti-spike antibody levels that may aid in the identification of patients lacking neutralizing antibodies against Omicron, the current dominant variant worldwide.

Our observations regarding overall seropositivity following a third vaccine dose and seroconversion rates in previous non-responders are largely in keeping with the observations in SOTRs (12, 14, 15). Specifically, among previously seronegative patients, 6/11 (54%) and 9/20 (45%) had seropositivity for anti-spike and anti-RBD antibodies when assessed one month post-third dose. While median binding antibody titres had declined at three months, the overall proportion of the cohort who had a robust anti-spike and anti-RBD antibody response was not significantly altered, providing reassuring evidence of a sustained response until this time point (17). Importantly, receipt of a third vaccine yielded a significant increase in the proportion of patients with neutralizing capacity against the WT, Beta, Delta and Omicron variants after one month; however, this response was inferior to that observed in healthy controls. Data on the development of an Omicron-specific neutralizing response among KTRs are limited, with rates of 12% (37) and 43% (38) reported at one month. We detected neutralizing antibody to Omicron in over 45% of our cohort at

one month, with sustained response in 38.5% at three months following the third mRNA vaccine dose.

At present, the optimum SARS-CoV-2 vaccination strategy in immunocompromised populations remains unclear. Our findings provide further evidence that the overall humoral response to a three-dose vaccine regimen in KTRs remains inferior to the immunocompetent population, suggesting that alternative strategies, including further vaccine doses, immunosuppressive modulation, or use of complementary agents such as long-acting monoclonal antibodies or anti-virals, may be necessary to induce a protective response against SARS-CoV-2 in transplanted patients (39-41). Concerningly, initial studies suggest that the 'value-add' of a fourth vaccine dose may be limited in those with a poor response to a three-dose vaccine series (41, 42). Among SOTRs with a weak serological response to prior vaccine doses, elevated titres of binding and neutralizing antibodies to many variants of concern were noted following a fourth dose; however, neutralization against Omicron was largely unchanged (43). In a KTR cohort, only 10% of previous nonresponders after three doses achieved an adequate response following a fourth dose (44). These data suggest that further widespread booster vaccination strategies may prove insufficient to ensure protection from infection, and that an unidentified subset of vaccinated transplant recipients will remain at high risk.

There is a clear imperative to identify correlates of protection from which those with poor serological response could be readily identified. Studies conducted following two-dose vaccination identified a number of clinical factors including age, transplant duration and use of mycophenolate or recent lymphocyte depletion therapies as associated with diminished

binding antibody response (45-49). However, in both our study, and the recent study by Kumar et al. in SOTRs (30), no demographic or transplant-related clinical characteristics emerged as significantly associated with the presence of an Omicron-specific neutralization response at one month post-third dose. In our cohort, those with detectable Omicron neutralizing antibody tended to have a lower median age and transplant vintage. In addition, they had a higher eGFR and a greater number of living donor transplant recipients (though these observations are likely linked). Improved vaccine response in proportion to eGFR is well-described amongst individuals with chronic kidney disease (50). Interestingly, patients who had detectable neutralizing antibody against at least one variant tended to have a greater dosing interval between doses 2 and 3, though this did not reach statistical significance. A recent publication by Hall and Ferreira *et al.* found that delayed-interval Pfizer-BioNTech (BNT162b2) mRNA COVID-19 vaccination was associated with enhanced humoral immune responses and robust T cell responses in SOTRs (51).

Both humoral and cell-mediated responses contribute to the development of protective immunity from SARS-CoV-2 (52). The immune correlates of protection are not fully understood; however, binding and neutralizing antibody titres directly correlate with protection from SARS-CoV-2 infection in the general population (33, 34, 53). Functional Tcell responses are also used to infer the degree of immune response to SARS-CoV-2 challenge, yet difficulties with standardization and scalability of these assays have limited their widespread use beyond research settings (54). While neutralizing antibody levels are highly predictive of the extent of immune protection from symptomatic SARS-CoV-2 infection (55), the assays required are typically cell-based, low throughput, and resource intensive in comparison to binding antibody assays (56). Binding antibody assays are higher

throughput and more readily scalable, and may thus represent the most accessible means of identifying the subset of patients who remain unprotected (57). Our findings point to binding antibody thresholds which may aid risk-stratification of patients and identification of those requiring prioritization for additional treatment strategies.

As our data and that of others demonstrate, the vaccine-induced Omicron-neutralizing capacity in SOTRs is inferior to that of all other variants (30, 31). The binding and neutralizing antibody thresholds associated with protection from infection represent moving targets, requiring re-definition in the setting of each new variant and associated degree of immune-evasion. A deeper understanding of the duration and magnitude of the immune response in transplant recipients would enable personalized care, and importantly, targeted allocation of scarce resources such as monoclonal antibodies, additional vaccination strategies or novel vaccine compositions within this population.

We acknowledge some limitations to this study. We could not evaluate the associations between neutralizing activity and clinical protection due to a paucity of SARS-CoV-2 breakthrough infections in our population during the study period. Our study size precluded definitive assessment of the impact of mixed vaccine regimens on the magnitude and durability of the antibody response following three-dose vaccination. However, our results, while underpowered, suggest that 3-dose mixed vaccine or Moderna-only regimens elicited stronger humoral responses. Superior immunogenicity from the mRNA-1273 (Moderna) vaccine has been reported amongst both hemodialysis patients and KTRs (36, 58). Further analyses will be required to confirm this result, and to clarify the clinical relevance of this potential finding. Finally, it is likely that the robustness of the protective immune response

to SARS-CoV-2 is related to the combined activity of both humoral and cell-mediated immunity, which was not investigated in this study.

In summary, ours is the first study to report on the durability of neutralizing antibodies to Omicron in a cohort of KTRs at three months following the third vaccine dose. Selection of a single anti-RBD-or anti-spike-antibody level threshold whereby neutralizing capability against Omicron is assured is challenging; nevertheless, the majority of KTRs with anti-spike and anti-RBD antibody titres above median levels in convalescent serum had detectable neutralizing antibody, and our work identifies specific binding antibody thresholds which may aid in the risk-stratification of patients. Importantly, quantitative binding antibody assays are relatively high throughput and scalable, making them a potentially attractive option worth further investigation (35).

Whilst future studies will be required to explore the contribution of cell-mediated immunity, affinity maturation and broadly neutralizing antibodies in this setting, our data suggest that antibody levels may aid in the identification of KTRs who remain highly susceptible to infection after vaccination, and for whom additional therapies may be necessary.

Methods

Patient population and study design

We conducted a prospective observational cohort study of kidney transplant recipients followed by the Renal Transplant Program of St. Michael's Hospital (Unity Health Toronto), Toronto, Ontario. All adult patients (aged ≥ 18 years) who had received a kidney transplant and had a functioning allograft were considered eligible for inclusion. Prevalent and incident patients were contacted in September 2021 when eligibility for third vaccine dosing in solidorgan transplant patients was confirmed by the Ontario Ministry of Health, and invited to participate in the study.

Clinical data sources

Patient demographics, clinical characteristics and covariates, and data related to COVID-19 vaccination or infection status were collected from the St. Michael's Hospital electronic health records.

Healthy controls

Healthy controls included health care workers and research staff recruited at Sunnybrook Health Sciences Centre (CTO No. 3604). All healthy controls were in self-reported good health and were ≥ 18 years old. Individuals with chronic conditions including chronic kidney disease, diabetes mellitus, hypertension, HIV, usage of immunosuppressive medication, and prior organ transplantation were excluded as healthy controls.

Serologic assays

Anti-spike, anti-receptor binding domain (Anti-RBD) and anti-nucleocapsid SARS-CoV-2 IgG antibodies were measured using an automated enzyme-linked immunosorbent assay (ELISA) as previously described (35, 36). Antibody levels were reported as relative ratios to a synthetic standard included as a calibration curve on each assay plate. VHH72-hFc1X7 (VHH-72-Fc) was used as the synthetic standard for anti-spike and anti-RBD antibodies as described previously (35), while human anti-nucleocapsid IgG (clone HC2003, GenScript, no. A02039) was used for anti-nucleocapsid antibody measurements. For VHH-72-hFc1X7, the llama single-domain monoclonal antibody VHH-72 was expressed as a human Fc fusion: VHH-72-hFc1X7 (PDB entry 6WAQ 1). Additional VHHs (NRCoV2–04 and NRCoV2–20) were isolated in-house from llamas immunized with recombinant SARS-CoV-2 trimeric spike ectodomain SmT1. VHH sequences were fused to an antibody-dependent cell-mediated cytotoxicity attenuated human IgG1 Fc domain (hFc1X7, US patent 2019 352 383A1). Our ELISA-based assay was harmonized with the WHO international standard unit – the Binding Antibody Unit (BAU). A table for conversion from relative ratios to BAU/mL is provided in Supplementary Table 4.

Thresholds for seropositivity (seroconversion) were determined as ≥3 standard deviations (SDs) from the log means of aggregated data from 300 pre-SARS-CoV-2 negative controls (collected prior to November 2019) (35). Seroconversion / seropositivity thresholds were 0.19, 0.186 and 0.396 for anti-spike, anti-RBD and anti-nucleocapsid antibodies, respectively. We considered the median levels of convalescent serum (taken 21–115 days after symptom onset in a cohort of 211 patients in the general population with a median age 59 years who had mild to severe SARS-CoV-2), as reflective of a robust antibody

response (35, 36); the medians were 1.38, 1.25 and 1.13 for anti-spike, anti-RBD, and antinucleocapsid antibodies, respectively.

Spike-pseudotyped lentivirus neutralization assay

Spike cDNAs encoding full-length wild-type SARS-CoV-2 bearing the D614G mutation, and full-length Beta (B.1.351) and Delta (B.1.617.2) variants were obtained from Twist Bioscience (San Francisco, CA). Spike cDNA encoding the full-length Omicron (B.1.1.529 (BA.1)) variant was obtained from Thermo Fisher Scientific (Waltham, MA). The spike expression constructs and pseudotyped lentivirus particles were generated in-house as described previously (30) and are freely available through CoVaRR-Net (https://nbcc.lunenfeld.ca/resources/). The neutralization assay was adapted from a previously validated SARS-CoV-2 spike pseudotyped lentivirus assay with constructs for Beta, Delta and Omicron variants, with minor modifications (59). Briefly, the viral packaging (psPAX2, Addgene, Waterntown, MA), the ZsGreen and luciferase reporter (pHAGE-CMV-Luc2-IRES-ZsGreen-W, kindly provided by Jesse Bloom) and the spike protein constructs were co-transfected into HEK293TN cells using jetPRIME transfection reagent (Polyplus, Illkirch, France). Pseudovirus particles were harvested 48 hours post transfection, and filtered (0.45 μ m filters) prior to aliquoting and storage at -80°C. The titre of each pseudovirus was determined by infecting HEK293T-ACE2/TMPRSS2 cells, and a virus dilution resulting in ~15% infection and > 1,000 relative luciferase units over the control was used in the neutralization assay (1:15 – 1:165 dilution of virus stock, ~400K relative luciferase units per pseudovirus).

The neutralization assay was conducted by first heat-inactivating (56°C, 30 mins) patient sera samples, then serially diluting sera in assay media at 3-fold (2.5-fold for Omicron testing) over 7 dilutions, starting at 1:22.5 dilution (1:20 for Omicron testing), and incubated with diluted virus at a 1:1 ratio for 1 hour at 37°C prior to addition to HEK293T-ACE2/TMPRSS2 cells. Following the 48 hours incubation, the infected cells were lysed using the BrightGlo Luciferase Assay System (Promega, Madison, WI) and the luminescence signals were quantified using a PerkinElmer Envision instrument. The 50% neutralization titres (ID50s) were calculated in GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA) using a nonlinear regression (log[inhibitor] versus normalized response – variable slope) algorithm. Both the HEK293TN and HEK293T-ACE2/TMPRSS2 cells were maintained at 85% confluency for no more than 25 passages. The dynamic range of the assay is 1:45-1:98,415 (1:40-1:24,414 for Omicron B.1.1.529 (BA.1)) for the detection of neutralizing capabilities of patient sera. Samples not meeting the minimum threshold were considered to be nonneutralizing.

Statistical analysis

Demographic and clinical characteristics of participants were compared using Wilcoxon rank sum test for continuous variables and Fisher's exact test for categorical variables. For paired samples, differences in anti-RBD and anti-spike antibody levels were compared using the Wilcoxon signed-ranks test, differences in proportions (e.g. response categories, proportion with neutralizing antibodies) were assessed using McNemar's test with continuity correction. ROC analysis was performed using the pROC package, and the optimal decision threshold for each analysis was identified using the "closest.topleft" metric (60). Antibody titre calculations were performed in GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA), all subsequent analyses were performed in R, version 4.1.2 (61).

Study approval

This study was registered with Clinical Trials Ontario and was approved by both the Sunnybrook Health Sciences Centre Research Ethics Board and locally by the St. Michael's Hospital Research Ethics Board with the Project ID 3604. All participants provided written informed consent prior to study participation.

Author Contributions

DAY, MAH, ACG, KY and CMM participated in study design. DAY, MJO, AL and MAH obtained funding. DAY, MAH and ACG provided supervision. QH and KTA performed the antibody quantification assays and related data acquisition and data analysis. CMM collated clinical data, analyzed the data, made figures and wrote the manuscript. All authors contributed to data interpretation, provided critical input to the manuscript, and approved the final version.

Data Availability

All or portions of the de-identified data are available upon reasonable request to the corresponding author, Dr. Caitríona McEvoy, or the senior author, Dr. Darren Yuen (darren.yuen@mail.utoronto.ca).

Acknowledgements

CMM is supported by the Dr. Mary Papantony Nephrology research fund. KTA is supported by a Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award. ACG is pillar lead for CoVaRR-Net and the Canada Research Chair (Tier 1) in Functional Proteomics. DAY was supported by a CIHR New Investigator Award. This work was supported by funds from the COVID Immunity Task Force (CITF) (grant No. 2122-HQ-000071) which is funded by the Government of Canada, and the St. Michael's Hospital Foundation. The robotics equipment used for the ELISA assays is housed in the Network Biology Collaborative Centre (NBCC) at the Lunenfeld-Tanenbaum Research Institute (ACG), a facility supported by Canada Foundation for Innovation funding, by the Ontario Government and by Genome Canada and Ontario Genomics (OGI-139). Sample intake and automated ELISA were performed by Geneviève Mailhot and Melanie Delgado Brand, and members of the NBCC, supervised by Karen Colwill, facilitated sample acquisition and data processing. We would like to thank the Nephrology Clinical Research team at St. Michael's Hospital, Unity Health Toronto (Michelle Nash, Niki Dacouris, Lindita Dapi, Weigiu Yuan, and Tiffany Thai) for collection and storage of study samples, and maintenance of the clinical research database. We would also like to thank the St. Michael's Hospital Kidney Transplant Clinic staff for their support, and finally all of the kidney transplant recipients for their participation in this study.

References

1. Hilbrands LB, Duivenvoorden R, Vart P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973-83.

2. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6.

3. Caillard S, Chavarot N, Francois H, Matignon M, Greze C, Kamar N, et al. Is COVID-19 infection more severe in kidney transplant recipients? Am J Transplant. 2021;21(3):1295-303.

Massie AB, Werbel WA, Avery RK, Chiang TP, Snyder JJ, Segev DL. Quantifying Excess
 Deaths Among Solid Organ Transplant Recipients in the COVID-19 Era. Am J Transplant.
 2022.

5. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021;325(21):2204-6.

Callaghan CJ, Mumford L, Curtis RMK, Williams SV, Whitaker H, Andrews N, et al.
 Real-world Effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca
 ChAdOx1-S Vaccines Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients.
 Transplantation. 2022;106(3):436-46.

 McEvoy CM, Lee A, Misra PS, Lebovic G, Wald R, Yuen DA. Real-world Impact of 2dose SARS-CoV-2 Vaccination in Kidney Transplant Recipients. Transplantation.
 2022;106(5):e279-e80.

8. Qin CX, Moore LW, Anjan S, Rahamimov R, Sifri CD, Ali NM, et al. Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation. 2021.

9. Rincon-Arevalo H, Choi M, Stefanski AL, Halleck F, Weber U, Szelinski F, et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021;6(60).

 Sattler A, Schrezenmeier E, Weber UA, Potekhin A, Bachmann F, Straub-Hohenbleicher H, et al. Impaired humoral and cellular immunity after SARS-CoV-2
 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131(14).

11. Tsapepas D, Paget K, Mohan S, Cohen DJ, Husain SA. Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021;78(2):314-7.

12. Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavayssiere L, et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant. 2021.

13. Hall VG, Ferreira VH, Ku T, Ierullo M, Majchrzak-Kita B, Chaparro C, et al. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients. N Engl J Med. 2021.

14. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med.

2021;385(7):661-2.

15. Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med. 2021.

16. Williams WW, Ingelfinger JR. Third Time's a Charm - Covid-19 Vaccine Hope for Solid-Organ Transplant Recipients. N Engl J Med. 2021.

17. Kamar N, Abravanel F, Marion O, Esposito L, Hebral AL, Medrano C, et al. Anti-SARS-CoV-2 spike protein and neutralizing antibodies at one and 3 months after 3 doses of SARS-CoV-2 vaccine in a large cohort of solid-organ-transplant patients. Am J Transplant. 2022.

18. Kumar D, Ferreira VH, Hall VG, Hu Q, Samson R, Ku T, et al. Neutralization of SARS-CoV-2 Variants in Transplant Recipients After Two and Three Doses of mRNA-1273 Vaccine : Secondary Analysis of a Randomized Trial. Ann Intern Med. 2021.

19. Karaba AH, Zhu X, Liang T, Wang KH, Rittenhouse AG, Akinde O, et al. A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients. Am J Transplant. 2021.

20. World Health Organization. Statement on Omicron sublineage BA.2 2022 [Accessed May 12th 2022]. Available from: <u>https://www.who.int/news/item/22-02-2022-statement-on-omicron-sublineage-ba.2</u>.

Mahase E. Covid-19: What do we know about omicron sublineages? BMJ.
 2022;376:o358.

22. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2021.

23. Piccoli L, Park YJ, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183(4):1024-42

e21.

24. Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv. 2021.

25. Schmidt F, Muecksch F, Weisblum Y, Da Silva J, Bednarski E, Cho A, et al. Plasma Neutralization of the SARS-CoV-2 Omicron Variant. N Engl J Med. 2022;386(6):599-601. 26. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, et al. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. Lancet Infect Dis. 2022.

27. Nemet I, Kliker L, Lustig Y, Zuckerman N, Erster O, Cohen C, et al. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection. N Engl J Med. 2021.

28. Arbel R, Hammerman A, Sergienko R, Friger M, Peretz A, Netzer D, et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19. N Engl J Med. 2021;385(26):2413-20.

29. Yoon SK, Hegmann KT, Thiese MS, Burgess JL, Ellingson K, Lutrick K, et al. Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers. N Engl J Med. 2022.

30. Kumar D, Hu Q, Samson R, Ferreira VH, Hall VG, Ierullo M, et al. Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine. Am J Transplant. 2022.

31. Benning L, Morath C, Bartenschlager M, Nusshag C, Kalble F, Buylaert M, et al. Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination. Clin J Am Soc Nephrol. 2022;17(1):98-106.

32. Al Jurdi A, Gassen RB, Borges TJ, Lape IT, Morena L, Efe O, et al. Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients. Kidney Int. 2022.

33. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection
against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):203240.

34. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021;385(16):1474-84.

35. Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, et al. A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination. Clin Transl Immunology. 2022;11(3):e1380.

36. Yau K, Chan CT, Abe KT, Jiang Y, Atiquzzaman M, Mullin SI, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ. 2022;194(8):E297-E305.

37. Jurdi AA, Gassen RB, Borges TJ, Lape IT, Morena L, Efe O, et al. Diminished antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients. medRxiv. 2022:2022.01.03.22268649.

38. Benning L, Morath C, Bartenschlager M, Kim H, Reineke M, Beimler J, et al. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variant after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. Am J Transplant. 2022.

39. Chapman JR, Wigmore SJ. Simple Vaccination Is not Enough for the Transplant Recipient. Transplantation. 2022;106(3):447-8.

40. Wise J. Covid-19: Evusheld is approved in UK for prophylaxis in immunocompromised people. BMJ. 2022;376:o722.

41. Kamar N, Abravanel F, Marion O, Romieu-Mourez R, Couat C, Del Bello A, et al. Assessment of 4 Doses of SARS-CoV-2 Messenger RNA-Based Vaccine in Recipients of a Solid Organ Transplant. JAMA Netw Open. 2021;4(11):e2136030.

42. Alejo JL, Mitchell J, Chiang TP, Abedon AT, Boyarsky BJ, Avery RK, et al. Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Transplantation. 2021;105(12):e280-e1.

43. Karaba AH, Johnston TS, Aytenfisu TY, Akinde O, Eby Y, Ruff JE, et al. A Fourth Dose of COVID-19 Vaccine Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal Vaccine Response. Transplantation. 2022.

44. Caillard S, Thaunat O, Benotmane I, Masset C, Blancho G. Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series. Ann Intern Med. 2022;175(3):455-6.

45. Magicova M, Zahradka I, Fialova M, Neskudla T, Gurka J, Modos I, et al.

Determinants of Immune Response to Anti-SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study. Transplantation. 2022.

46. Marion O, Del Bello A, Abravanel F, Faguer S, Esposito L, Laure Hebral A, et al. Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients. Transplant Direct. 2022;8(1):e1248.

47. Russo G, Lai Q, Poli L, Perrone MP, Gaeta A, Rossi M, et al. SARS-COV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications. Clin Transplant. 2021:e14495.

48. Yi SG, Moore LW, Eagar T, Graviss EA, Nguyen DT, Ibrahim H, et al. Risk Factors Associated With an Impaired Antibody Response in Kidney Transplant Recipients Following 2 Doses of the SARS-CoV-2 mRNA Vaccine. Transplant Direct. 2022;8(1):e1257.

49. Kantauskaite M, Muller L, Kolb T, Fischer S, Hillebrandt J, Ivens K, et al. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients. Am J Transplant. 2022;22(2):634-9.

50. Krueger KM, Ison MG, Ghossein C. Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2020;75(3):417-25.

51. Hall VG, Ferreira VH, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K, et al. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022.

52. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529).

53. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43-50.

54. Shrotri M, van Schalkwyk MCI, Post N, Eddy D, Huntley C, Leeman D, et al. T cell response to SARS-CoV-2 infection in humans: A systematic review. PLoS One. 2021;16(1):e0245532.

55. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-11.

56. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9(1):680-6.

57. Werbel WA, Segev DL. SARS-CoV-2 antibody testing for transplant recipients: A tool to personalize protection versus COVID-19. Am J Transplant. 2022.

58. Wijtvliet V, Arien KK, Abrams S, Couttenye MM, Mestrez F, Marien J, et al. mRNA-1273 vaccine (Moderna): a better option than BNT162b2 (Pfizer) in kidney transplant recipients and dialysis patients? Nephrol Dial Transplant. 2022;37(4):799-803.

59. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight. 2020;5(19).

60. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-

source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.

2011;12:77.

61. R Core Team. R: A Language and Environment for Statistical Computing. 4.1.2 ed. Vienna, Austria2021.

Figure Legends

Figure 1: Binding antibody response at 1 and 3 months post-third mRNA vaccine dose Levels of A) serum anti-RBD and B) anti-spike IgG in 44 participants with blood samples drawn pre- and at 1 month post-third dose. Anti-RBD and anti-spike antibody levels had significantly increased in the study population at 1 month post-third dose (Wilcoxon signed rank test, $p = 3.65 \times 10^{-10}$ and 7.51 x 10^{-10} , respectively). The proportion of kidney transplant recipients now exhibiting a robust antibody response with both anti-spike antibody (McNemar test with continuity correction, $p = 5.1 \times 10^{-5}$) and anti-RBD antibody (McNemar test with continuity correction, p = 0.001) was significantly increased as shown. Levels of C) serum anti-RBD and D) anti-spike IgG in 26 participants with additional blood samples drawn at 3 months post-third dose. Anti-RBD and anti-spike antibody levels had decreased at 3 months post-third dose (Wilcoxon signed rank test, $p = 8.2 \times 10^{-5}$ (anti-RBD) and p = 0.84(anti-spike)). The proportion of kidney transplant recipients now exhibiting a robust antibody response with both anti-spike antibody (McNemar test with continuity correction, p = 1) and anti-RBD antibody (McNemar test with continuity correction, p = 0.48) was not significantly altered as shown.

For all images: The values depicted are relative ratios against a synthetic standard. Serum volume 0.0625 μ L. Threshold lines and marked values demonstrate seropositivity (green dashed line) and the median convalescent response (blue dashed line). Individual values are colored to depict the response level as shown in the legend. Solid black lines indicate the median ratio values for each grouping. * p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

Figure 2: Detection of neutralizing antibodies against SARS-CoV-2 wild-type, Beta, Delta and Omicron (BA.1) variants at 1 and 3 months post-third mRNA vaccine dose. A) Neutralizing antibodies detected in 44 participants with blood samples drawn pre- and at 1 month post-third dose. The proportion of kidney transplant recipients with detectable neutralizing antibody (Log₁₀ID₅₀ >0) was significantly increased for all variants (McNemar test with continuity correction; wild-type p =0.026, Beta p= 0.005, Delta p = 0.005; McNemar's exact test: Omicron p=0.0037). B) Neutralizing antibodies detected in 26 participants with blood samples drawn pre- and at 1 and 3 months post-third dose. The proportion of kidney transplant recipients with detectable neutralizing antibody (Log₁₀ID₅₀ >0) was not significantly altered compared to month 1 (McNemar test with continuity correction; p=1 for all comparisons. For all images: Paired values are linked with black dashed lines. Solid black lines in each violin plot indicate the median Log₁₀ID₅₀ values for each variant. * p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

Figure 3: Comparison of neutralizing antibody levels detected in healthy controls and kidney transplant recipients pre- and post-third vaccine dose. Neutralizing antibodies detected in 44 kidney transplant recipients (KTRs) and 13 healthy controls (HC) before the third vaccine dose (pre-third dose) and at month 1 post-third dose. For all images: Paired values are linked with black dashed lines. Solid black lines in each violin plot indicate the median Log₁₀ID₅₀ values for each variant.

Figure 4: Comparison of neutralizing antibody levels in healthy controls and responding kidney transplant recipients pre- and post-third vaccine dose. For each variant, neutralizing antibody levels for responding kidney transplant recipients (KTRs)- i.e. those with detectable neutralizing antibody (Log₁₀ID₅₀ >0), were plotted alongside healthy controls (HC) and differences between medians was assessed using Wilcoxon rank sum test. * $p \le 0.05$, ** $p \le 0.01$.

Figure 5: Threshold levels of binding antibody response associated with detectable neutralizing antibody.

Receiver operating characteristic (ROC) analysis of anti-RBD and anti-spike antibody levels across **A)** Wild-type, **B)** Beta, **C)** Delta and **D)** Omicron variants, for classification of the presence or absence of detectable neutralizing antibody ($Log_{10}ID_{50} > 0$). Areas under the curve (AUC) for anti-spike (yellow) and anti-RBD (blue) are marked. Further details on the threshold values are found in Supplemental Table 3.















Tables

Table 1: Characteristics of the study cohort

	Pre-3 rd dose and	Pre-3 rd dose, Month
	Month 1 blood	1 and Month 3
	samples	blood samples
	N=44	N=26
Male Sex N (%)	35 (79.5)	23 (88.5)
Age (years) at Dose 3	55.5	56
Median (IQR)	(45.8 – 63)	(48.8 - 63.8)
Transplant Vintage at Dose 3 (Months)	43.1	39.6
Median (IQR)	(7 – 142)	(10.2 - 145.4)
eGFR (ml/minute/1.73 m ²)	53	48.9
Median (IQR)	(36.3 – 73.6)	(35.7 – 64.9)
Donor type N (%)		
Deceased donor	29 (66)	18 (69.2)
Living donor	15 (34)	8 (30.8)
Immunosuppression at time of Dose 3 N (%)		
Prednisone	41 (93.2)	24 (92.3)
Anti-metabolite	34 (77.3)	20 (77)
(Mycophenolate Sodium/Mofetil)		
CNI - Tacrolimus	40 (91)	23 (88.5)
CNI - Cyclosporine	4 (9)	3 (11.5)
On triple agent immunosuppression	31 (70.5)	18 (69.2)
BMI kg/m ²	25.7	26.5
Median (IQR)	(23.4 – 29.5)	(23.9 – 29.5)
Previous COVID-19 Infection N (%)	2 (4.5)	1 (3.8)
Initial (2-dose) Vaccine series N (%)		
Pfizer-BioNTech (BNT162b2)	35 (79.5)	22 (84.6)
Moderna (mRNA-1273)	8 (18.1)	3 (11.5)
Mixed	1 (2.3)	1 (3.8)
3-dose vaccine series N (%)		
Pfizer-BioNTech (BNT162b2)	35 (79.5)	22 (84.6)
Moderna (mRNA-1273)	7 (15.9)	3 (11.5)
Mixed	2 (4.6)	1 (3.8)
Dose and blood testing intervals (days)		
Median (IQR)		
Dose 1 to Dose 2	21	21
	(21 – 31)	(21 – 27.5)
Dose 2 to Dose 3	152	134.5
	(127.3 – 185.7)	(122 -158.5)
Dose 2 to Pre-booster blood testing	149.5	133.5
	(124 – 174)	(119.5 – 154.5)
Dose 3 to Month 1 blood testing	26.5	25.5
	(20.75 – 32.25)	(18.8 – 29.8)
Dose 3 to Month 3 blood testing	NA	84.5 (79.5 – 90)

Abbreviations: BMI: body mass index; CNI: Calcineurin Inhibitor; COVID-19: SARS-CoV-2; eGFR: estimated glomerular filtration rate; IQR: Inter-quartile range; mRNA: messenger ribonucleic acid.

Table 2. Summary of binding and neutralizing antibody profiles of KTRs prior to, and at 1 and 3 Months after third mRNA SARS-CoV-2 vaccine dose.

Binding	Relative ratio (median [IQR])		No. (%) participants with		No. (%) participants with				
Antibody			seropositivity		antibody levels ≥ median				
	Pre- third dose N=44	1 month post 3 rd dose N=44	Three months post 3 rd dose N=26	Pre- third dose N=44	1 month post 3 rd dose N=44	Three months post 3 rd dose N=26	Pre- third dose N=44	1 month post 3 rd dose N=44	Three months post 3 rd dose N=26
Anti-spike	0.871 [0.218- 1.264]	1.447 [1.149 – 1.549]	1.454 [0.535 – 1.60]	33 (75)	39 (88.6)	23 (88.4)	8 (18.2)	28 (63.6)	14 (53.8)
Anti-RBD	0.212 [0.033- 0.597]	1.198 [0.249 – 1.478]	0.479 [0.066 – 1.373]	24 (54.5)	33 (75)	15 (57.6)	3 (6.8)	20 (45.5)	8 (30.7)
Anti- nucleocapsid	0.063 [0.044- 0.097]	0.06 [0.046 – 0.084]	0.0597 [0.0489 - 0.069]	2 (4.5)	2 (4.5)	0 (0)	0 (0)	0 (0)	0 (0)
Neutralizing antibody	Log ₁₀ ID ₅₀	(median [IQR]]) (of respon	nding patier	nts)		No. (%) pa detectable antibody	irticipants w e neutralizir	vith ng
Neutralizing antibody	Log ₁₀ ID ₅₀ Pre-third N=44	(median [IQR] dose]) (of respon 1 month p dose N=44	nding patier	nts) Three mont dose N=26	hs post 3 rd	No. (%) pa detectable antibody Pre- third dose N=44	nticipants w e neutralizir 1 month post 3 rd dose N=44	vith ng Three months post 3 rd dose N=26
Neutralizing antibody Wild Type	Log ₁₀ ID ₅₀ Pre-third N=44 2.20 [1.81	(median [IQR] dose . – 2.56])) (of respon 1 month p dose N=44 3.28 [2.62	nding patien post 3 rd – 3.55]	nts) Three mont dose N=26 2.84 [2.18 –	hs post 3 rd	No. (%) pa detectable antibody Pre- third dose N=44 21 (47.7)	1 month post 3 rd dose N=44 32 (72.2)	vith ng Three months post 3 rd dose N=26 16 (61.5)
Neutralizing antibody Wild Type Beta	Log ₁₀ ID ₅₀ Pre-third N=44 2.20 [1.81 1.68 [1.53	(median [IQR] dose . – 2.56] . – 1.99])) (of respon 1 month p dose N=44 3.28 [2.62 2.76 [2.26	nding patien post 3 rd – 3.55] – 3.15]	nts) Three mont dose N=26 2.84 [2.18 – 2.51 [2.19 –	hs post 3 rd 3.40]	No. (%) pa detectable antibody Pre- third dose N=44 21 (47.7) 11 (25)	1 month post 3 rd dose N=44 32 (72.2) 25 (56.8)	vith ng Three months post 3 rd dose N=26 16 (61.5) 12 (46.2)
Neutralizing antibody Wild Type Beta Delta	Log ₁₀ ID ₅₀ Pre-third N=44 2.20 [1.81 1.68 [1.53 2.06 [1.74	(median [IQR] dose 2.56] 1.99])) (of respon 1 month p dose N=44 3.28 [2.62 2.76 [2.26 3.01 [2.52	nding patien post 3 rd - 3.55] - 3.15] - 3.37]	nts) Three mont dose N=26 2.84 [2.18 – 2.51 [2.19 – 2.66 [2.09 –	hs post 3 rd • 3.40] • 3.08] • 3.21]	No. (%) pa detectable antibody Pre- third dose N=44 21 (47.7) 11 (25) 14 (31.8)	1 month post 3 rd dose N=44 32 (72.2) 25 (56.8) 28 (63.6)	vith bg Three months post 3 rd dose N=26 16 (61.5) 12 (46.2) 14 (53.9)

Abbreviations: IQR: Interquartile range.

	Non-Responder	Responder	р
	N= 24	N=20	
Male Sex N (%)	19 (79.2)	16 (80.0)	1
Age (years) at Dose 3	57.50 [51.75, 65.25]	52.50 [41.25, 58.25]	0.106
Median (IQR)			
Transplant Vintage at Dose 3 (Months)	58.62 [8.12, 131.79]	24.73 [3.47, 142.16]	0.316
Median (IQR)			
eGFR (ml/minute/1.73 m ²)	44.30 [36.05, 63.27]	66.03 [47.92, 79.18]	0.07
Median (IQR)			
Donor Type (%)			
Deceased Donor	19 (79.2)	10 (50.0)	0.059
Living Donor	5 (20.8)	10 (50.0)	
Immunosuppression at time of Dose 3 N (S	%)		
Prednisone	23 (95.8)	18 (90.0)	
			0.583
Anti-metabolite	19 (79.2)	15 (75.0)	1
(Mycophenolate			
Sodium/Mofetil)			
CNI - Tacrolimus	21 (87.5)	19 (95.0)	0.614
CNI - Cyclosporine	3 (12.5)	1 (5.0)	
On triple agent immunosuppression	18 (75.0)	13 (65.0)	0.522
BMI (%)			0.392
(median [IQR])	23.91 [22.63, 27.21]	27.89 [24.77, 31.59]	
Previous COVID-19 Infection	2 (8.3)	0 (0.0)	0.493
N (%)			
3-dose Vaccine series N (%)			
Pfizer- BioNTech (BNT162b2)	21 (87.5)	14 (70.0)	0.208
Moderna (mRNA-1273)	3 (12.5)	4 (20.0)	
Mixed	0 (0.0)	2 (10.0)	
Dose and blood testing intervals (days) Media	ın (IQR)		
Dose 1 to Dose 2	21.00 [21.00, 34.75]	21.00 [21.00, 28.50]	0.593
Dose 2 to Dose 3	140.00 [122.50,	175.00 [130.25,	0.179
	173.75]	192.75]	
Dose 3 to Month 1 blood samples	25.00 [20.00, 32.25]	28.00 [21.75, 33.25]	0.322

Table 3: Characteristics of participant with Omicron-specific neutralizing response

Abbreviations: BMI: body mass index; CNI: Calcineurin Inhibitor; COVID-19: SARS-CoV-2; eGFR: estimated glomerular filtration rate; IQR: Inter-quartile range; mRNA: messenger ribonucleic acid.

	Non-Responder	Responder	р
	N= 12	N=32	
Male Sex N (%)	10 (83.3)	25 (78.1)	1
Age (years) at Dose 3	58.00 [54.50, 64.50]	53.00 [44.25, 62.25]	0.158
Median (IQR)			
Transplant Vintage at Dose 3 (Months)	79.93 [23.99-131.79]	24.73 [3.47, 142.16]	0.316
Median (IQR)			
eGFR (ml/minute/1.73 m ²)	44.30 [38.03-61.35]	55.91 [38.29, 77.79]	0.171
Median (IQR)			
Donor Type (%)			
Deceased Donor	9 (75.0)	20 (62.5)	0.5
Living Donor	3 (25.0)	12 (37.5)	
Immunosuppression at time of Dose 3	N (%)		
Prednisone	11 (91.7)	30 (93.8)	1
Anti-metabolite			
(Mycophenolate Sodium/Mofetil)			
	11 (91.7)	23 (71.9)	0.241
CNI - Tacrolimus	11 (91.7)	29 (90.6)	1
CNI - Cyclosporine	1 (8.3)	3 (9.4)	
On triple agent immunosuppression	10 (83.3)	21 (65.6)	0.459
BMI (%)			0.518
(median [IQR])	23.88 [23.36, 26.66]	25.89 [24.19, 29.86]	
Previous COVID-19 Infection N (%)	1 (8.3)	1 (3.1)	0.476
3-dose Vaccine series N (%)			
Pfizer- BioNTech (BNT162b2)	11 (91.7)	24 (75.0)	0.677
Moderna (mRNA-1273)	1 (8.3)	6 (18.7)	
Mixed	0 (0.0)	2 (6.3)	
3 rd dose manufacturer N (%)			
Pfizer-BioNTech (BNT162b2)	11 (91.7)	26 (81.2)	0.653
Moderna (mRNA-1273)	1(8.3)	6 (18.8)	
Dose and blood testing intervals (days)			
Median (IQR)			
Dose 1 to Dose 2	21.00 [21.00, 28.25]	21.00 [21.00, 31.00]	0.896
Dose 2 to Dose 3	134.50 [120.75, 151.25]	173.00 [133.25, 196.50]	0.051
Dose 3 to Month 1 blood samples	23.50 [16.75, 33.00]	26.50 [21.75, 31.25]	0.413

Table 4: Characteristics of participants with detectable neutralizing response to at least one variant

Abbreviations: BMI: body mass index; CNI: Calcineurin Inhibitor; COVID-19: SARS-CoV-2; eGFR: estimated glomerular filtration rate; IQR: Inter-quartile range; mRNA: messenger ribonucleic acid.